RBRC00916, B6.Cg-Irf9<tm1Ttg>/TtgRbrc

RBRC No. RBRC00916
Type Targeted MutationCartagena wks
Species Mus musculus
Strain name B6.Cg-Irf9<tm1Ttg>/TtgRbrc
Former Common name IRF-9 KO/C57BL/6J ; p48<-/->; IRF-9<-/->, IRF-9 Knockout mouse, C57BL/6J
H-2 Haplotype No Data
ES cell line TT2 [(C57BL/6NCrlj x CBA/JNCrlj)F1]
Donor strain (C57BL/6 x CBA)F1 via TT2 EC cell line
Background strain C57BL/6JJcl
Appearance
1 Appearance black
Genotype No Data
Strain development Developed by Tadatsugu Taniguchi, Graduate School of Medicine and Faculty of Medicine, University of Tokyo. RBRC00915: Backcrossed to BALB/c (N8 generations), RBRC00916: Backcrossed to C57BL/6J (over N13 generations).
Strain description IRF-9 gene knockout mice. Homozygous mutant mice exhibit lower serum interferon levels in response to viral infection. BALB/c background (RBRC00915), C57BL/6 background (RBRC00916).
Colony maintenance Homozygote x Homozygote
Health Report
Gene Details
Promoter No Data
1 Symbol Irf9
Symbol name interferon regulatory factor 9
Chromosome 14
Common name Irf-9, p48
Symbol description No Data
Promoter mouse phosphoglycerate kinase promoter (PGK promoter)
2 Symbol neo
Symbol name neomycin resistance gene (E. coli)
Chromosome 14
Common name neo; neomycin;
Symbol description No Data
References Genes Cells. 1996 Jan;1(1):115-24.

Essential and non-redundant roles of p48 (ISGF3 gamma) and IRF-1 in both type I and type II interferon responses, as revealed by gene targeting studies.
Research applications Immunology and Inflammation Research
Specific Term and Conditions The following terms and conditions will be requested by the DEPOSITOR.
The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR.
In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested.
The RECIPIENT shall inform the DEPOSITOR about the purpose of the use of the BIOLOGICAL RESOURCE and shall limit the use within the scope of the purpose described in this Agreement. The RECIPIENT shall inform the DEPOSITOR about the results obtained by the use of the BIOLOGICAL RESOURCE.
Additional information
1 Genetic Background
2 Taniguchi Lab HP
3 Genotyping protocol <PCR>
Depositor Taniguchi, Tadatsugu (The University of Tokyo, Graduate School of Medicine) Taniguchi, Tadatsugu
Strain Status /
Availability
(Expected delivery)


Frozen
Cryopreserved embryos : Within 1 month
Recovered litters from cryopreserved embryos : 2-4 months

Live
Live mouse :
BRC mice in Publications
Title Journal
(PMID)
Author
The type I interferon-alpha mediates a more severe neurological disease in the absence of the canonical signaling molecule interferon regulatory factor 9. J Neurosci.30(3): 1149-57 (2010).(20089923)
Hofer MJ, Li W, Lim SL, Campbell IL.
MICE DEFICIENT FOR STAT1 BUT NOT STAT2 OR IRF9 DEVELOP A LETHAL CD4+ T-CELL-MEDIATED DISEASE FOLLOWING INFECTION WITH LYMPHOCYTIC CHORIOMENINGITIS VIRUS. J Virol. (2012).(22496215)
Hofer MJ, Li W, Manders P, Terry R, Lim SL, King NJ, Campbell IL.
IRF7-DEPENDENT, TYPE I INTERFERON PRODUCTION INDUCES LETHAL IMMUNE-MEDIATED DISEASE IN STAT1 KO MICE INFECTED WITH LCMV. J Virol. (2014).(24760883)
Li W, Hofer MJ, Jung SR, Lim SL, Campbell IL.